Genetic and epigenetic profiling of BRCA1/2 in ovarian tumors reveals additive diagnostic yield and evidence of a genomic BRCA1/2 DNA methylation signature

Poly-ADP-ribose-polymerase inhibitor (PARPi) treatment is indicated for advanced-stage ovarian tumors with BRCA1/2 deficiency. The “BRCAness” status is thought to be attributed to a tumor phenotype associated with a specific epigenomic DNA methylation profile. Here, we examined the diagnostic impact...

Descripción completa

Detalles Bibliográficos
Autores principales: Aref-Eshghi, Erfan, McGee, Jacob D., Pedro, Victor P., Kerkhof, Jennifer, Stuart, Alan, Ainsworth, Peter J., Lin, Hanxin, Volodarsky, Michael, McLachlin, Catherine Meg, Sadikovic, Bekim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7449880/
https://www.ncbi.nlm.nih.gov/pubmed/32483276
http://dx.doi.org/10.1038/s10038-020-0780-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7449880/
https://www.ncbi.nlm.nih.gov/pubmed/32483276
http://dx.doi.org/10.1038/s10038-020-0780-4

Ejemplares similares